熱門資訊> 正文
Vaccinex表示，阿尔茨海默氏症候选人受到更多早期数据的鼓舞
2024-08-14 22:21
- Vaccinex (NASDAQ:VCNX) said that additional data from an early-stage trial of its Alzheimer's drug pepinemab found that an endpoint indicates the drug may slow decline in brain metabolic activity.
- The company said that in the phase 1b/2 SIGNAL-AD study, there was a statistically significant difference in the FDG-PET signal in the medial temporal cortex after 12 months of treatment compared to placebo.
- When the initial data was presented in late July, Vaccinex stock dropped precipitously as the results indicated pepinemab might be most effective in treating mild cognitive impairment, a very early stage of Alzheimer's, rather than subsequent dementia.
More on Vaccinex
- Vaccinex stock plunges 24% on mixed results for Alzheimer's study
- Financial information for Vaccinex
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
